Vertex (VRTX): H.C. Wainwright Comments on VX-661 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Goldman Sachs Comments on Vertex (VRTX)
May 2, 2014 9:39 AM EDTGoldman Sachs maintained a Neutral rating on Vertex (NASDAQ: VRTX) with a price target of $64.00.
Analyst Terence Flynn said, "In our view 1Q results were uneventful and the focus remains on... More
Vertex (VRTX) Bullish Stance Reiterated at Needham & Company after Q1 Results, Encouraging VX-661-Ivacaftor Phase 2 Data
May 2, 2014 7:41 AM EDTNeedham & Company analyst Alan Carr reiterated a Buy rating and $95 price target on Vertex (NASDAQ: VRTX) following Q1 results and 'encouraging' VX-661-ivacaftor phase 2 data.
Carr commented, "Vertex reported 1Q14 financial results yesterday and announced positive top-line results from a Phase 2... More
Vertex Pharmaceuticals, Inc. (VRTX) Posts Q1 Loss of 65c/Share; Reports Statistically Significant KALYDECO + VX-661 Ph. 2 Data
May 1, 2014 4:09 PM EDTVertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q1 EPS of ($0.65), $0.03 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $118.5 million versus the consensus estimate of $134.46 million.
Vertex also announced that treatment with the combination of VX-661 and KALYDECO® (ivacaftor) in a 28-day Phase 2 study showed statistically significant improvements in lung function (FEV1) in people with both the F508del mutation and G551D mutation who were already taking KALYDECO. VX-661 was added to patients ongoing KALYDECO treatment for four weeks to evaluate the safety of the combination regimen... More
